Form 4: Pasithea Therapeutics Executive Awarded Stock Options
SEC Form 4
Graeme Currie, Chief Development Officer of Pasithea Therapeutics, was granted fully vested stock options exercisable immediately.
Summary
- Graeme Currie, Chief Development Officer of Pasithea Therapeutics Corp., was granted stock options on March 1, 2024.
- The options, awarded under the company's 2023 Stock Incentive Plan, are for 5,938 shares of common stock at an exercise price of $8.34 per share.
- The options vested immediately and became exercisable on March 1, 2024, with an expiration date of February 28, 2034.
- A 1-for-20 reverse stock split was effected by the Issuer on January 2, 2024, which adjusted the share amounts and exercise prices of outstanding equity awards.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice, and the immediate vesting could be seen as a sign of confidence in the executive. However, it's not a major event that would drastically alter the company's outlook.
Positives
- The granting of stock options to a key executive aligns their interests with those of the shareholders.
- The immediate vesting of the options suggests confidence in the executive's contributions to the company's success.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives. The size and terms of the grant are typical for an executive at Currie's level.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Comparable companies such as Biohaven Pharmaceutical Holding Company Ltd. and Neurocrine Biosciences, Inc. also utilize stock options as part of their executive compensation plans.
- The vesting schedule and exercise price are generally in line with industry norms, although immediate vesting is less common than graded vesting over several years.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for the executive to drive company performance.
- Employees may see this as a positive sign of investment in leadership.
Key Dates
| Date | Description |
|---|---|
| 01/02/2024 | Issuer effected a reverse stock split of its common stock at a ratio of 1-for-20. |
| 03/01/2024 | Date of the stock option grant and when the options became exercisable. |
| 02/28/2034 | Expiration date of the stock options. |
Keywords
stock options, Pasithea Therapeutics, Graeme Currie, Chief Development Officer, equity awards, reverse stock split, KTTA
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.